India's Dr Reddy's posts strong Q4 net on generics sales
Indian drug maker Dr Reddy's Laboratories Ltd posted strong quarterly net profit on sales of generics, including a cheap version of GlaxoSmithKline Plc's anti-nausea blockbuster, Zofran, but said profit would fall this year.
bdnews24.com News Service
bdnews24.com
Published :
19 May 2007, 10:25 AM
Updated :
17 Aug 2022, 03:11 PM
MUMBAI, May 19 (bdnews24.com/Reuters) - Indian drug maker Dr Reddy's Laboratories Ltd posted strong quarterly net profit on sales of generics, including a cheap version of GlaxoSmithKline Plc's anti-nausea blockbuster, Zofran, but said profit would fall this year.
The company expects core businesses to grow strongly in the year ahead but sees lower profit in 2007/08. The fiscal year that ended in March saw one-time gains from a 180-day exclusivity period for Zofran's generic equivalent, and authorised generics.
"Revenue will fall especially when you consider the 180-day exclusivity will wind down," Chief Executive GV Prasad told Reuters in a telephone interview from Hyderabad.
Asked if net profit would fall this fiscal year, he said: "Obviously. We had some very special opportunities, they are not likely to recur. So net profit will be a lower number."
Dr Reddy's, which received a setback earlier this month when a US court upheld a patent protecting Japanese firm Eisai Co Ltd's Aciphex drug, posted January-March net profit of 3.25 billion rupees versus a loss of 236 million rupees reported a year ago.
A Reuters poll of 11 brokers had forecast quarterly net profit of 1.76 billion rupees.
Dr Reddy's, India's only New York Stock Exchange-listed drug maker, said full-year net profit jumped to 9.33 billion rupees from 1.6 billion rupees the previous year.
"The numbers look very good. The stock has underperformed for some time but the outlook is positive," said Sarabjit Kour Nangra, an analyst at Angel Broking.
Dr Reddy's trades at around 14 times forecast earnings, against multiples of 21 for Cipla and nearly 24 for Ranbaxy.
Last month, Ranbaxy Laboratories, India's top drug maker by sales, reported an above-forecast 79 percent rise in net profit and raised its 2007 sales forecast, but Cipla Ltd's profit fell 34 percent, lagging forecasts.
Sun Pharmaceutical Industries reported on Friday that its net profit rose 48 percent to 2.12 billion rupees in the January-March quarter.
Sales of generics -- cheaper versions of drugs that have gone off patent -- in Western markets are expected to sustain earnings growth for India's top drug makers.
In April, the world's largest drug maker, Pfizer Inc, cut its 2007 forecast as generic competition hit demand for its Norvasc hypertension drug.
Shares in Dr Reddy's closed 1.8 percent lower at 665.75 rupees in a flat Mumbai market. The stock fell more than 10 percent in January-March, underperforming a 3.8 percent drop on Mumbai's healthcare sub-index. Ranbaxy also fell 10 percent, while Cipla lost 6 percent.
bdnews24.com/srs/1622 hrs